Pureos Bioventures
Venture capitalPfäffikon · Seed–Series C · 11 people tracked
Investment thesis
Pureos Bioventures provides venture capital to private companies developing innovative therapeutics for severe diseases and conditions. The firm emphasizes the next generation of biological drugs and novel drug formats, aiming to improve patients' lives by advancing new treatments. It backs strong founding teams with development programs that make a meaningful difference for patients, and its portfolio spans oncology, fibrosis, immune-mediated inflammatory diseases, neurological disorders, ophthalmology, cardiovascular disease, vaccines and rare diseases. The team combines career venture capitalists, biotech founders, former pharma and biotech executives, research scientists, medical doctors and experienced drug developers.
Source: firm website, verified Aug 3, 2026.
Team · 11 people
from public directories
What they invest in
from 4 of 22 portfolio companiesBiotech ×4Healthtech ×3Medical Devices ×3Deep Tech ×1
HQs:Switzerland×1France×1United States×1
Investments · 22 tracked
founders shown can be your intro pathClinical stage oncology company developing cancer drugs paired with companion diagnostics; went public on NASDAQ (ACRV) in 2022.
Watertown, US
Araris develops proprietary antibody-drug conjugate (ADC) linker technology that enables one-step attachment of payloads to native antibodies for targeted cancer therapy.
BiotechMedical DevicesBasel, CH
Dragan Grabulovski(Co-founder and CEO)Philipp Spycher(Co-founder and Chief Scientific Officer)Isabella Attinger-Toller(Co-founder)
PulseSight Therapeutics develops non-viral, plasmid-based gene therapies delivered via a proprietary electro-transfection system into the ciliary muscle to treat severe retinal diseases causing blindness.
BiotechHealthtechMedical Devices
Tridek-One Therapeutics develops bispecific antibodies that agonize the CD31 ITIM inhibitory checkpoint receptor to modulate immune cell activation for inflammatory and autoimmune diseases.
BiotechDeep TechHealthtechParis, FR
Clinical-stage biopharmaceutical company developing treatments for cancer and fibrotic diseases.
Basel-area incubator and accelerator helping launch biotech companies in Switzerland.
Seattle and Singapore-based biotech developing next-generation multi-payload antibody-drug conjugates for cancer treatment.
French biotech developing gene therapies for neurological diseases; acquired by uniQure in 2021.
Platform and product company engineering potent, specific T cell receptor (TCR) therapies.
French startup developing novel treatments for respiratory and inflammatory diseases.
Clinical-stage biopharmaceutical company developing precision monoclonal antibodies against difficult cancer targets.
Developer of antibody therapeutics targeting butyrophilin checkpoint molecules for cancer; acquired by Ipsen in 2025.
Boston-based preclinical biotech developing antibody therapeutics targeting fibrotic mediators and myofibroblasts.
Swiss clinical-stage biotech developing therapeutic antibodies for virus infections and cancer.
Swiss startup developing regenerative therapies for eye and central nervous system diseases.
Clinical-stage company developing novel therapies for orphan renal diseases.
Tavo Biotherapeutics develops novel treatments for glaucoma and retinal diseases, focusing on disease-modifying therapies that target the root biological mechanisms of vision loss.
BiotechHealthtechMedical Devices
Exits · 2
IPOs and acquisitions across the tracked portfolioAcrivon TherapeuticsNASDAQ: ACRVImCheck Therapeuticsacq. by Ipsen
Frequently asked questions
- What stage does Pureos Bioventures invest at?
- Pureos Bioventures invests at the Seed, Series A, Series B, Series C stages.
- What sectors does Pureos Bioventures focus on?
- Pureos Bioventures focuses on Biotech, Healthtech, Medical Devices.
- Where is Pureos Bioventures located?
- Pureos Bioventures is headquartered in Pfäffikon, CH.
Images
Co-investors · 11
Kurma Partners is a European healthcare-focused investment firm that co-founds and finances biotech and healthcare companies, working closely with research centers to translate scientific discoveries into high-tech companies.
Norwest is a venture and growth equity investment firm that has backed over 700 companies across sectors including AI, retail, and healthcare, working alongside entrepreneurs from early to late-stage growth.
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.
Andera Partners is an asset management firm specializing in private equity that partners with companies and their management to support sustainable growth. It has backed 377 companies over more than 20 years.
Advent Life Sciences is a trans-Atlantic venture capital firm investing in early and mid-stage life sciences companies across the UK, Europe and the USA.
Adjuvant Capital is a venture capital firm that finances life science technologies addressing high-burden public health challenges, aiming to deliver both social and financial returns.
Earlybird Venture Capital is a European venture capital firm that backs early-stage technology founders with capital, strategic support, and access to an international network.
MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.
Pfizer Ventures is the corporate venture arm of Pfizer that invests in life science innovation across oncology, inflammation & immunology, cardiovascular, metabolic/obesity, and vaccines, as well as platform technology companies aligned with Pfizer's strategic focus areas.
HealthCap is a life science venture capital investor and company creator that backs innovative healthcare ideas, people, and companies aiming to impact healthcare and society.
4BIO Capital is a London-based venture capital firm investing in life sciences, with a focus on advanced therapies that address high unmet medical and social needs.
Firms observed investing alongside Pureos Bioventures, from public investor directories. Shared companies are the overlap with Pureos Bioventures's recorded portfolio.
Similar investors
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.
Sofinnova is an investment firm that partners with biotech companies from inception through growth, supporting drug development, the regulatory process, company building, and IPO.
Kaiser Permanente Ventures is the corporate venture capital arm investing in healthcare companies that address real needs and deliver value for patients, providers, healthcare delivery systems, and communities.
Foresite Capital is a multi-stage investment firm focused on healthcare and life sciences, backing companies across all stages of growth. It applies a data science-driven approach to invest in businesses leveraging biology and big data to transform healthcare.
Korea Investment Partners is a South Korea-based venture capital firm that invests across multiple stages from early-stage startups through growth and buyout transactions, including venture debt and mezzanine financing. The firm operates across venture capital, middle market, and growth equity investment categories.